Pfizer is a leading international pharmaceutical company that can trace its history back more than 170 years. Its business units include Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines, and Internal Medicine. Pfizer was the first company (along with partner BioNTech) to have a Covid vaccine approved for general use. It has proven to be highly effective with minimal side effects. The company has also developed a drug to treat the virus.
Shares of pharmaceutical giant Pfizer Inc. (NYSE: PFE) have hit new 52-week lows and are bumping along at levels not seen for 15 years.
Wealth Builder
Sorry!
Only current subscribers of the Internet Wealth Builder may view the details of this recommendation.
Income Investor
Pfizer has continued to reward investors with dividend increases. It is now in a position to reward them with a rising share price. Tariffs may cause its shares to fall further, but the biggest potential is on the upside. The stock is a buy for patient investors seeking above-average income and capital gains potential. We will add PFE to our recommended list. The shares were trading on April 7 at $22.31. - Adam Mayers
Sorry!
Only current subscribers of The Income Investor may view the details of this recommendation.
Interactive Performance Chart
PFE was first recommended here on April 27, 2020